BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31176194)

  • 1. Seizure prevalence, contributing factors, and prognostic factors in patients with leptomeningeal disease.
    Zima LA; Tulpule S; Samson K; Shonka N
    J Neurol Sci; 2019 Aug; 403():19-23. PubMed ID: 31176194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
    Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
    Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience.
    Kingston B; Kayhanian H; Brooks C; Cox N; Chaabouni N; Redana S; Kalaitzaki E; Smith I; O'Brien M; Johnston S; Parton M; Noble J; Stanway S; Ring A; Turner N; Okines A
    Breast; 2017 Dec; 36():54-59. PubMed ID: 28968585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of leptomeningeal disease following hypofractionated stereotactic radiotherapy for intact and resected brain metastases.
    Nguyen TK; Sahgal A; Detsky J; Atenafu EG; Myrehaug S; Tseng CL; Husain Z; Heyn C; Maralani P; Ruschin M; Perry J; Soliman H
    Neuro Oncol; 2020 Jan; 22(1):84-93. PubMed ID: 31412120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast brain metastases are associated with increased risk of leptomeningeal disease after stereotactic radiosurgery: a systematic review and meta-analysis.
    Brown DA; Lu VM; Himes BT; Burns TC; Quiñones-Hinojosa A; Chaichana KL; Parney IF
    Clin Exp Metastasis; 2020 Apr; 37(2):341-352. PubMed ID: 31950392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis.
    Yust-Katz S; Garciarena P; Liu D; Yuan Y; Ibrahim N; Yerushalmi R; Penas-Prado M; Groves MD
    J Neurooncol; 2013 Sep; 114(2):229-35. PubMed ID: 23756727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of whole brain radiation therapy for leptomeningeal carcinomatosis.
    Hirano Y; Konishi K; Ejima Y
    Int J Clin Oncol; 2020 Jul; 25(7):1432-1439. PubMed ID: 32274614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).
    Ferguson SD; Bindal S; Bassett RL; Haydu LE; McCutcheon IE; Heimberger AB; Li J; O'Brien BJ; Guha-Thakurta N; Tetzlaff MT; Tawbi H; Davies MA; Glitza IC
    J Neurooncol; 2019 May; 142(3):499-509. PubMed ID: 30847840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posterior fossa metastases: risk of leptomeningeal disease when treated with stereotactic radiosurgery compared to surgery.
    Siomin VE; Vogelbaum MA; Kanner AA; Lee SY; Suh JH; Barnett GH
    J Neurooncol; 2004; 67(1-2):115-21. PubMed ID: 15072456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of risk factors associated with leptomeningeal disease after resection of brain metastases.
    Morshed RA; Saggi S; Cummins DD; Molinaro AM; Young JS; Viner JA; Villanueva-Meyer JE; Goldschmidt E; Boreta L; Braunstein SE; Chang EF; McDermott MW; Berger MS; Theodosopoulos PV; Hervey-Jumper SL; Aghi MK; Daras M
    J Neurosurg; 2023 Aug; 139(2):402-413. PubMed ID: 36640095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical Resection of Brain Metastases and the Risk of Leptomeningeal Recurrence in Patients Treated With Stereotactic Radiosurgery.
    Johnson MD; Avkshtol V; Baschnagel AM; Meyer K; Ye H; Grills IS; Chen PY; Maitz A; Olson RE; Pieper DR; Krauss DJ
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):537-43. PubMed ID: 26867883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of cerebrospinal fluid tumor cell count in leptomeningeal disease from solid tumors.
    Barbour AB; Blouw B; Taylor LP; Graber JJ; McGranahan T; Blau M; Halasz LM; Lo SS; Tseng YD; Venur V; Yang JT
    J Neurooncol; 2024 May; 167(3):509-514. PubMed ID: 38441840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis.
    Torrejón D; Oliveira M; Cortes J; Sanchez-Olle G; Gómez P; Bellet M; Saura C; Peg V; Rovira A; Di Cosimo S
    Breast; 2013 Feb; 22(1):19-23. PubMed ID: 23137566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic radiosurgery for focal leptomeningeal disease in patients with brain metastases.
    Wolf A; Donahue B; Silverman JS; Chachoua A; Lee JK; Kondziolka D
    J Neurooncol; 2017 Aug; 134(1):139-143. PubMed ID: 28536993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
    Chorti E; Kebir S; Ahmed MS; Keyvani K; Umutlu L; Kanaki T; Zaremba A; Reinboldt-Jockenhoefer F; Knispel S; Gratsias E; Roesch A; Ugurel S; Scheffler B; Schadendorf D; Livingstone E; Meier F; Glas M; Zimmer L
    Eur J Cancer; 2021 May; 148():395-404. PubMed ID: 33789203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis.
    Ojerholm E; Lee JY; Thawani JP; Miller D; O'Rourke DM; Dorsey JF; Geiger GA; Nagda S; Kolker JD; Lustig RA; Alonso-Basanta M
    J Neurosurg; 2014 Dec; 121 Suppl():75-83. PubMed ID: 25434940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic significance of surgically treated hydrocephalus in leptomeningeal metastases.
    Jung TY; Chung WK; Oh IJ
    Clin Neurol Neurosurg; 2014 Apr; 119():80-3. PubMed ID: 24635931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution.
    Mandel JJ; Yust-Katz S; Cachia D; Wu J; Liu D; de Groot JF; Yung AW; Gilbert MR
    J Neurooncol; 2014 Dec; 120(3):597-605. PubMed ID: 25168214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy for leptomeningeal disease in breast cancer.
    Bartsch R; Jerzak KJ; Larrouquere L; Müller V; Le Rhun E
    Cancer Treat Rev; 2024 Jan; 122():102653. PubMed ID: 38118373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical and anatomic factors predict development of leptomeningeal disease in patients with melanoma brain metastases.
    Lowe SR; Wang CP; Brisco A; Whiting J; Arrington J; Ahmed K; Yu M; Robinson T; Oliver D; Etame A; Tran N; Beer Furlan A; Sahebjam S; Mokhtari S; Piña Y; Macaulay R; Forsyth P; Vogelbaum MA; Liu JKC
    Neuro Oncol; 2022 Aug; 24(8):1307-1317. PubMed ID: 35092434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.